A population-based, retrospective study looked at the associations between cannabis use and effects on heart health.
In a study published in the journal Addiction in September 2023, researchers used compiled data from five Canadian health databases to examine the connections between cannabis use disorder (CUD) and cardiovascular disease (CVD) (1). The purpose of the study, researchers explained, was to address the lack of conclusive and recent literature on the topic by measuring the association between CUD and CVD (1). The study examined data from 2012 to 2019 on a total of 59,528 individuals, half of whom had a CUD diagnosis (1).
In reportedly one of the first Canadian studies looking into these associations, researchers did not find a causal link between CUD and CVD, but did conclude that compared to individuals without CUD, “Canadian adults with cannabis use disorder appear to have an approximately 60% higher risk of experiencing incident adverse cardiovascular disease events,” (1).
Researchers explained the significance of their findings for patients (1). “Importantly, this evidence suggests that cannabis use may place a healthier population at increased risk of major cardiovascular events,” the Conclusion stated (1). “As a result, our study points to the importance of educating our patients about the potential risks associated with cannabis use and CUD.”
The study’s lead researcher, Anees Bahji, MD, commented on the implications of the study (2). "The relationship between cannabis use and cardiovascular events is complex and may also be influenced by factors such as the method of cannabis consumption, the presence of other co-occurring health conditions, and individual variations in response to cannabis," Dr. Bahji said (2). "Further research is needed to better understand these mechanisms and the overall impact on cardiovascular health."
Peter Grinspoon, MD, primary care physician at Massachusetts General Hospital and cannabis specialist also commented on the findings (2). “The presence of cannabis use disorder isn't very accurate in helping us to determine anything," Dr. Grinspoon said of this study (2). “That said, if you take too high a dosage of cannabis, it can cause anxiety which, in turn, can trigger an arrhythmia [an irregular heartbeat] or possibly a coronary event, so, inpatients with a history of coronary disease, particularly recent, unstable coronary disease, or with a history of arrhythmia, I treat very carefully if at all with medicinal cannabis.”
Hear what Dr. Grinspoon has to say on medical cannabis in our Cannabis Science and Technology in-depth interview.
References
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.